- Home
- KSCP vs BTAI Comparison
KSCP vs BTAI Comparison
Compare KSCP & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSCP
- BTAI
- Stock Information
- Founded
- KSCP 2013
- BTAI 2017
- Country
- KSCP United States
- BTAI United States
- Employees
- KSCP N/A
- BTAI N/A
- Industry
- KSCP Telecommunications Equipment
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- KSCP Telecommunications
- BTAI Health Care
- Exchange
- KSCP Nasdaq
- BTAI Nasdaq
- Market Cap
- KSCP 46.4M
- BTAI 52.7M
- IPO Year
- KSCP 2022
- BTAI 2018
- Fundamental
- Price
- KSCP $5.45
- BTAI $4.23
- Analyst Decision
- KSCP Strong Buy
- BTAI Strong Buy
- Analyst Count
- KSCP 3
- BTAI 4
- Target Price
- KSCP $17.00
- BTAI $40.00
- AVG Volume (30 Days)
- KSCP 368.0K
- BTAI 12.0M
- Earning Date
- KSCP 08-12-2025
- BTAI 08-12-2025
- Dividend Yield
- KSCP N/A
- BTAI N/A
- EPS Growth
- KSCP N/A
- BTAI N/A
- EPS
- KSCP N/A
- BTAI N/A
- Revenue
- KSCP $11,014,000.00
- BTAI $868,000.00
- Revenue This Year
- KSCP $11.16
- BTAI N/A
- Revenue Next Year
- KSCP $34.72
- BTAI $597.46
- P/E Ratio
- KSCP N/A
- BTAI N/A
- Revenue Growth
- KSCP N/A
- BTAI N/A
- 52 Week Low
- KSCP $2.45
- BTAI $1.17
- 52 Week High
- KSCP $28.57
- BTAI $13.36
- Technical
- Relative Strength Index (RSI)
- KSCP 44.00
- BTAI 52.74
- Support Level
- KSCP $5.35
- BTAI $3.41
- Resistance Level
- KSCP $6.43
- BTAI $4.20
- Average True Range (ATR)
- KSCP 0.40
- BTAI 0.56
- MACD
- KSCP 0.01
- BTAI -0.22
- Stochastic Oscillator
- KSCP 31.05
- BTAI 37.44
About KSCP Knightscope Inc.
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.